A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer

Trial Profile

A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
  • Indications Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate901
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 27 Jun 2017 Planned number of patients changed from 1045 to 1097.
    • 19 Apr 2017 Planned primary completion date changed from 1 Sep 2020 to 26 Apr 2020.
    • 10 Mar 2017 Planned End Date changed from 29 Nov 2022 to 1 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top